• Home |
  • Contact |
  • Subscription |
  • Forward looking statement |
  • Site map |
  • Français |
  • Text size: A A A
Ambrilia Biopharma
  • Corporate
    • + Vision & strategy
    • + Management
    • + Board of directors
    • + Scientific advisory board
    • + Corporate governance
  • Investors
    • + News
    • + Events
    • + Conference calls and webcasts
    • + Shareholder information
    • + Stock information
    • + Financial reports
    • + Analysts
    • + Investor contact
  • Product pipeline
    • + Acromegaly - Octreotide
    • + Prostate cancer - PCK3145
    • + Prostate cancer - Goserelin
    • + Cancer - NGR-Delivery Technology
    • + HIV/AIDS - Protease Inhibitors
    • + HIV/AIDS - Integrase Inhibitors
    • + HIV/AIDS - Entry Inhibitors
    • + HCV - Polymerase Inhibitors
    • + HCV - Entry Inhibitors
    • + Influenza A - M2 Proton Channel Inhibitors
    • + Diagnostic - PSP94
    • + Diagnostic - Colopath® / ColorectAlert™
    • + Scientific library
  • Licensing opportunities
  • Careers

Site map

  • Corporate
    • + Vision & strategy
    • + Management
    • + Board of directors
    • + Scientific advisory board
    • + Corporate governance
  • Investors
    • + News
    • + Events
    • + Conference calls and webcasts
    • + Shareholder information
    • + Stock information
    • + Financial reports
    • + Analysts
    • + Investor contact
  • Product pipeline
    • + Acromegaly - Octreotide
    • + Prostate cancer - PCK3145
    • + Prostate cancer - Goserelin
    • + Cancer - NGR-Delivery Technology
    • + HIV/AIDS - Protease Inhibitors
    • + HIV/AIDS - Integrase Inhibitors
    • + HIV/AIDS - Entry Inhibitors
    • + HCV - Polymerase Inhibitors
    • + HCV - Entry Inhibitors
    • + Influenza A - M2 Proton Channel Inhibitors
    • + Diagnostic - PSP94
    • + Diagnostic - Colopath® / ColorectAlert™
    • + Scientific library
  • Licensing opportunities
  • Careers
  • Contact

Copyright © 1998-2006 Ambrilia Biopharma. All rights reserved. - Terms of use